The current COVID-19 pandemic is a global health emergency, causing severe respiratory disease requiring hospitalization and even death in a significant proportion of the human population. Although therapeutic intervention including novel pharmaceuticals or the passive transfer of immune serum from recovered patients could provide short-term relief in mortality and morbidity, the development of a successful vaccine will ultimately be required to prevent the continued spread and seasonal recurrence of this disease within the human population. However, very little is known about either the quality of adaptive immune response or the viral antigen targets that are necessary to prevent the infection. Here we propose to evaluate a novel vaccination approach recently developed in my laboratory that we will now apply to SARS-CoV-2. Specifically, we will generate Vaccinia virus (VacV) vectors expressing the SARS-CoV-2 Spike (S) protein that have been engineered to targeted the S protein for MHC-II presentation. Overall, this study will evaluate whether VacV expressing SARS-CoV-2 S protein could be a potential vaccine candidate and whether the ?immunogenicity? of the S protein can be enhanced by targeting the protein for MHC-II presentation.

Public Health Relevance

The current COVID-19 pandemic is a global health emergency, causing severe respiratory disease requiring hospitalization and even death in a significant proportion of the human population. Here, we will evaluate whether Vaccinia virus vectors expressing modified versions of the SARS-CoV-2 Spike protein generate high- affinity neutralizing antibodies against the virus. These studies will contribute to the long-term goal of developing an effective vaccine that will prevent the continued spread and seasonal recurrence of this disease within the human population.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
3R01AI132404-03S1
Application #
10143716
Study Section
Program Officer
Lapham, Cheryl K
Project Start
2020-05-18
Project End
2021-08-31
Budget Start
2020-05-18
Budget End
2020-08-31
Support Year
3
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Hobbs, Samuel J; Osborn, Jossef F; Nolz, Jeffrey C (2018) Activation and trafficking of CD8+ T cells during viral skin infection: immunological lessons learned from vaccinia virus. Curr Opin Virol 28:12-19
Osborn, Jossef F; Mooster, Jana L; Hobbs, Samuel J et al. (2017) Enzymatic synthesis of core 2 O-glycans governs the tissue-trafficking potential of memory CD8+ T cells. Sci Immunol 2: